Achieving accurate, comprehensive, and fast offline similar sequence search optimal for safety assessment of nucleic acid drugs.
Providing related services aimed at shortening drug development time for nucleic acid drugs.
Rational design of CRISPR/Cas target
Go to Service site
launch
comprehensive support for nucleic acid drugs, from design to safety evaluation.
Go to Service site
launchOverview
High-speed search for short base sequences
Nucleic acid drugs often have short sequences of around 20 bases, allowing for efficient safety evaluation.
Accurate mismatch, indel and fuzzy search
This enables accurate and easy searches that are essential for safety evaluation of nucleic acid drugs.
Trusted and proven in the safety evaluation of nucleic acid drugs
This can be used as reliable search results for approval applications for nucleic acid drugs.
Searchable offline
Because it runs on USB (SSD), confidential information will not be leaked to the outside.
Relaxing search restrictions
Search restrictions have been relaxed to reduce the burden on the server, allowing for efficient searches.
Highlighting of interesting genes
You can easily extract only the important information from a huge number of search results.
Search support scripts for easy bulk searches
Operations such as performing multiple searches at once can be performed from the UI screen, allowing anyone to search efficiently.
Update in 2026 edition
The ability to set an upper limit on the number of search results has been added, enabling shorter search times during batch searches and better load control during search processing.
When the target database for searching is fixed, a feature has been added to keep the database resident in memory, further reducing search time.
Database
GGGenome Drug Discovery Basic Pack 2026 Edition
Search Data (9 species, 42 databases)
D3G / RefSeq are all the latest versions
D3G was established by the Kawai Group of the AMED Genomic Drug Discovery Foundation Promotion Research Project (FY2017-FY2022) and is currently maintained by the Kawaji Group's "Research on establishing a foundation for the exploration of new drug discovery targets using genomic information" (FY2023-). It is widely used in nucleic acid drug discovery and pharmaceutical affairs, and can also be searched on the GGGenome web version.
Database Options
Optional databases
You can add databases that are searchable on the web version of GGGenome published by DBCLS.
Custom database
You can also add your own sequence database.
Operating environment
This product is compatible with 64-bit versions of Windows.
Windows 11 Pro version 21H2 or later, or Enterprise/Education version 21H2 or later
Windows 10 Pro 21H1 or later, or Enterprise/Education 20H2 or later
Enable Hyper-V (may be exclusive with virtualization software such as VMWare)
Memory: 16GB or more (Docker for Windows must allocate at least 8GB)
Interviews / Case studies
Detail
Using the GGGenome packaged version to evaluate off-target effects of oligonucleotide therapeutics
Detail
Adopting the GGGenome packaged version to assess off-target risk for antisense oligonucleotides
Detail
Integrating the GGGenome packaged version into Genome Editing Cloud®, a cloud-based open platform for genome editing support
Detail
Deepening life science research with GGGenome, ultra-fast genome sequence search
FAQ
Contact Us for a Consultation or Quote
We can help you select the right product, add optional databases, or build a custom nucleotide sequence database. Feel free to contact us, even if you’re just exploring your options.
Contact Us by Email
info_bio@retrieva.jp
© 2026 Retrieva, Inc. All rights reserved.
About Retrieva’s Bio AI Business
Learn more